Sodium-glucose cotransporter-2 inhibitor use in type 2 diabetes mellitus is associated with a lower rate of atrial arrhythmias in a hospitalized real-world population
In this real-world, comorbid inpatient cohort, SGLT2i treatment was associated with a lower incidence of atrial arrhythmias. Prospective randomized trials evaluating SGLT2i as specific atrial fibrillation pharmacotherapy are underway.
Authors
- Carmine G. De Pasquale (ORCID: https://orcid.org/0000-0001-5025-6117)
- Derek P. Chew (ORCID: https://orcid.org/0000-0003-3593-296X)
- Kristina Lambrakis (ORCID: https://orcid.org/0000-0002-6221-0244)
- Anand N. Ganesan (ORCID: https://orcid.org/0000-0002-2734-3025)
- Ju Tan (ORCID: https://orcid.org/0000-0001-8385-4623)
- Kathryn Tiver (ORCID: https://orcid.org/0000-0003-3340-2113)
Institutions
- Flinders University (AU)
- Flinders Medical Centre (AU)
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1016/j.hroo.2024.12.004
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- AstraZeneca
- National Heart Foundation of Australia
- Cardiac Society of Australia and New Zealand